12:00 AM
 | 
Sep 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PRTX-100: Phase Ib data

Final data from a dose-escalation, South African Phase Ib trial in 37 patients with active RA who were receiving methotrexate showed that once-weekly PRTX-100 missed the primary disease activity response endpoint of improving the number of patients with DAS28-CRP score <3.2 points at week 6 vs. placebo. Protalex said that PRTX-100 did not reduce C-reactive protein (CRP) levels, a component of the DAS28-CRP scale, even in patients who achieved a reduction in swollen and...

Read the full 359 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >